Literature DB >> 21314752

Long-term opioid blockade and hedonic response: preliminary data from two open-label extension studies with extended-release naltrexone.

Charles P O'Brien1, David R Gastfriend, Robert F Forman, Edward Schweizer, Helen M Pettinati.   

Abstract

The emergence of extended-release naltrexone (XR-NTX) raises the opportunity to explore the role of endorphin blockade on hedonic response during long-term alcohol dependence treatment. A hedonic survey was administered to 74 alcohol dependent patients treated for an average of 3.5 years with nearly continuous month-long intramuscular XR-NTX. The paper-and-pencil, one-time survey asked patients about the degree of pleasure they experienced in the past 90 days with drinking alcohol, sex, exercise and other daily activities. The data revealed lower pleasure ratings for alcohol than for sex, exercise and 10 other common activities. Mean responses to drinking alcohol and gambling were significantly lower than to listening to music, sex, reading, being with friends, eating good food, eating spicy food, and playing video/card games. This effect was independent of XR-NTX dose or duration. Although this exploratory study lacked baseline data, a comparison group or control for the impact of patient discontinuation, the data indicate the feasibility of examining long-term hedonic response in recovery. The differential hedonic ratings suggest that, in patients who persist with long-term continuous therapy, XR-NTX may selectively inhibit the pleasure associated with drinking alcohol, compared to a variety of other activities. © American Academy of Addiction Psychiatry.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21314752      PMCID: PMC3895092          DOI: 10.1111/j.1521-0391.2010.00107.x

Source DB:  PubMed          Journal:  Am J Addict        ISSN: 1055-0496


  34 in total

1.  Stimulation of endorphin neurotransmission in the nucleus accumbens by ethanol, cocaine, and amphetamine.

Authors:  M F Olive; H N Koenig; M A Nannini; C W Hodge
Journal:  J Neurosci       Date:  2001-12-01       Impact factor: 6.167

2.  Opioid receptor blockade eliminates mood effects of aerobic gymnastics.

Authors:  A Järvekülg; A Viru
Journal:  Int J Sports Med       Date:  2002-04       Impact factor: 3.118

Review 3.  Opioid peptides and the control of human ingestive behaviour.

Authors:  Martin R Yeomans; Richard W Gray
Journal:  Neurosci Biobehav Rev       Date:  2002-10       Impact factor: 8.989

Review 4.  Endogenous opioids and addiction to alcohol and other drugs of abuse.

Authors:  Christina Gianoulakis
Journal:  Curr Top Med Chem       Date:  2004       Impact factor: 3.295

5.  Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial.

Authors:  James C Garbutt; Henry R Kranzler; Stephanie S O'Malley; David R Gastfriend; Helen M Pettinati; Bernard L Silverman; John W Loewy; Elliot W Ehrich
Journal:  JAMA       Date:  2005-04-06       Impact factor: 56.272

6.  Naltrexone alters subjective and psychomotor responses to alcohol in heavy drinking subjects.

Authors:  M E McCaul; G S Wand; T Eissenberg; C A Rohde; L J Cheskin
Journal:  Neuropsychopharmacology       Date:  2000-05       Impact factor: 7.853

7.  Nucleus accumbens opioid, GABaergic, and dopaminergic modulation of palatable food motivation: contrasting effects revealed by a progressive ratio study in the rat.

Authors:  Min Zhang; Christian Balmadrid; Ann E Kelley
Journal:  Behav Neurosci       Date:  2003-04       Impact factor: 1.912

8.  Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis.

Authors:  Stephanie S O'Malley; Suchitra Krishnan-Sarin; Conor Farren; Rajita Sinha; Mary Jeanne Kreek
Journal:  Psychopharmacology (Berl)       Date:  2002-01-22       Impact factor: 4.530

9.  Vivitrex, an injectable, extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for 1 month in rats.

Authors:  Raymond T Bartus; Dwaine F Emerich; Joyce Hotz; Marc Blaustein; Reginald L Dean; Brigido Perdomo; Anthony S Basile
Journal:  Neuropsychopharmacology       Date:  2003-11       Impact factor: 7.853

10.  Chronic ethanol consumption by C57BL/6 mice promotes tolerance to its interoceptive cues and increases extracellular dopamine, an effect blocked by naltrexone.

Authors:  Lawrence D Middaugh; Karen K Szumlinski; Yancy Van Patten; Angela-Leigh Bandy Marlowe; Peter W Kalivas
Journal:  Alcohol Clin Exp Res       Date:  2003-12       Impact factor: 3.455

View more
  16 in total

1.  Anhedonia, depression, anxiety, and craving in opiate dependent patients stabilized on oral naltrexone or an extended release naltrexone implant.

Authors:  Evgeny Krupitsky; Edwin Zvartau; Elena Blokhina; Elena Verbitskaya; Valentina Wahlgren; Marina Tsoy-Podosenin; Natalia Bushara; Andrey Burakov; Dmitry Masalov; Tatyana Romanova; Arina Tyurina; Vladimir Palatkin; Tatyana Yaroslavtseva; Anna Pecoraro; George Woody
Journal:  Am J Drug Alcohol Abuse       Date:  2016-07-19       Impact factor: 3.829

2.  Extended-release naltrexone for methamphetamine dependence among men who have sex with men: a randomized placebo-controlled trial.

Authors:  Phillip O Coffin; Glenn-Milo Santos; Jaclyn Hern; Eric Vittinghoff; Deirdre Santos; Tim Matheson; Grant Colfax; Steven L Batki
Journal:  Addiction       Date:  2017-08-29       Impact factor: 6.526

3.  Effects of extended-release naltrexone on the brain response to drug-related stimuli in patients with opioid use disorder.

Authors:  Zhenhao Shi; An-Li Wang; Kanchana Jagannathan; Victoria P Fairchild; Charles P O'Brien; Anna Rose Childress; Daniel D Langleben
Journal:  J Psychiatry Neurosci       Date:  2018-07       Impact factor: 6.186

4.  Effects of extended-release naltrexone on the brain response to drug-related stimuli in patients with opioid use disorder.

Authors:  Zhenhao Shi; An-Li Wang; Kanchana Jagannathan; Victoria P Fairchild; Charles P O'Brien; Anna Rose Childress; Daniel D Langleben
Journal:  J Psychiatry Neurosci       Date:  2018-02-23       Impact factor: 6.186

5.  Long-term follow-up study of community-based patients receiving XR-NTX for opioid use disorders.

Authors:  Arthur Robin Williams; Vincent Barbieri; Kaitlyn Mishlen; Frances R Levin; Edward V Nunes; John J Mariani; Adam Bisaga
Journal:  Am J Addict       Date:  2017-03-22

Review 6.  The genetics of the opioid system and specific drug addictions.

Authors:  Orna Levran; Vadim Yuferov; Mary Jeanne Kreek
Journal:  Hum Genet       Date:  2012-05-01       Impact factor: 4.132

Review 7.  Advancing addiction treatment: what can we learn from animal studies?

Authors:  Peter H Wu; Kalynn M Schulz
Journal:  ILAR J       Date:  2012

Review 8.  Pharmacological means of reducing human drug dependence: a selective and narrative review of the clinical literature.

Authors:  Shih-Ku Lin
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

9.  Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence.

Authors:  Evgeny Krupitsky; Edwin Zvartau; Elena Blokhina; Elena Verbitskaya; Valentina Wahlgren; Marina Tsoy-Podosenin; Natalia Bushara; Andrey Burakov; Dmitry Masalov; Tatyana Romanova; Arina Tyurina; Vladimir Palatkin; Tatyana Slavina; Anna Pecoraro; George E Woody
Journal:  Arch Gen Psychiatry       Date:  2012-09

10.  Maternally administered sustained-release naltrexone in rats affects offspring neurochemistry and behaviour in adulthood.

Authors:  Waleed O Farid; Andrew J Lawrence; Elena V Krstew; Robert J Tait; Gary K Hulse; Sarah A Dunlop
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.